There are 27 small molecule protein‐protein interaction (PPI) modulators in Phase I, II, and III clinical trials targeting cancer, viruses, autoimmune disorders, and as immune suppression agents. Targeting PPIs as an antibiotic drug discovery strategy remains in relative infancy by comparison. However, a number of molecules are in development which target PPI within the replisome, divisome, transcriptome, and translatome are showing significant promise at the medicinal chemistry stage of drug development. Hence, the success of future PPI agents as antibiotics will build upon the techniques and design strategies of these molecules.

中文翻译：

---

蛋白质-蛋白质相互作用作为抗生素的靶标：药物化学的观点。

在I，II和III期临床试验中，有27种小分子蛋白-蛋白质相互作用（PPI）调节剂针对癌症，病毒，自身免疫性疾病并作为免疫抑制剂。相比之下，将PPI定位为抗生素药物发现策略仍处于初期阶段。但是，在药物开发的药物化学阶段，针对复制体，divisome，转录组和翻译组中的PPI的许多分子正在开发中。因此，未来PPI试剂作为抗生素的成功将建立在这些分子的技术和设计策略上。